Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business UpdatesGlobeNewsWire • 05/14/26
Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026GlobeNewsWire • 05/05/26
Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost ReductionGlobeNewsWire • 04/29/26
Autolus Therapeutics plc (AUTL) Discusses Advances in B-cell Precursor Acute Lymphoblastic Leukemia Treatment and Clinical Trial Insights TranscriptSeeking Alpha • 04/08/26
Autolus Therapeutics: Q4 Earnings Highlight Importance Of Autoimmune Data CatalystsSeeking Alpha • 03/27/26
Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business UpdatesGlobeNewsWire • 03/27/26
Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026GlobeNewsWire • 03/16/26
Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026GlobeNewsWire • 01/12/26
Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell Shuttle™ PlatformGlobeNewsWire • 01/06/26
Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell ShuttleTM PlatformBusiness Wire • 01/06/26
Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025GlobeNewsWire • 12/08/25
Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025GlobeNewsWire • 12/08/25
NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹GlobeNewsWire • 11/25/25
Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in LondonGlobeNewsWire • 11/13/25
Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business UpdatesGlobeNewsWire • 11/12/25
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025GlobeNewsWire • 11/03/25